Over the next few years we are going to see the development and marketing of a plethora of new tests related to the diagnosis and prognosis of prostate cancer. Some of these tests may have high utility and value. Others are likely to have a much lower value (but still see high use). As an example, let’s look at the (relatively new) Confirm MDx for Prostate Cancer test. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Confirm MDx, epigenetic, gene, methylation, repeat, risk | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 